ATGEN
DEAD

Serial Number

86300715

Owner

ATGen Co., Ltd.

Attorney

Margaret C. McHugh

Filing Date

Jun 4, 2014

Add to watchlist:

No watchlists yet
View on USPTO

ATGEN Trademark

Serial Number: 86300715

ATGEN is a trademark filed by ATGen Co., Ltd. on June 4, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

ATGen Co., Ltd. (4 trademarks)

ATGen, Institut Pasteur Korea 2F
Gyeonggi-do 463-400 , KR

Entity Type: 99

Trademark Details

Filing Date

June 4, 2014

Registration Date

Not Registered

Published for Opposition

May 26, 2015

Goods & Services

Custom manufacture of proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens, antibodies and hormones; Custom manufacture of in vitro diagnostic devices and antibody detection kits

Proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens, antibodies and hormones for veterinary or medical purposes: hormones; diagnostic kits for medical diagnostic use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic activators in the nature of proteins for use in diagnostic kits for disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic preparations for medical diagnostic use; diagnostic reagents for medical diagnostic use

Online retail store services featuring proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens, antibodies and hormones; online retail store services featuring vitro diagnostic devices and antibody detection kits

Proteins in raw material form for scientific and medical research; Proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens and antibodies for use by others in manufacturing pharmaceutical and veterinary preparations; proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens and antibodies for scientific and research purposes; diagnostic kits for clinical laboratory use, namely kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status diagnostic kits for medical laboratory use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for medical research use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for clinical research use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA in disease diagnosis screening, and immune status; diagnostic preparations for clinical laboratory use and medical laboratory use; diagnostic preparations for clinical research use other than for medical use; diagnostic reagents for clinical laboratory use, medical laboratory use, medical research use and clinical research use

medical research services; scientific research, namely, conducting clinical research trials; research and development of medicines based on protein and peptide therapeutic applications; medical diagnostic services; biological DNA cloning services; protein expression services in the field of biotechnology, namely, DNA gene cloning services, purification process development; laboratory services relating to the production of monoclonal antibodies; medical and scientific research services, namely, monoclonal antibody development, generation and screening and design related thereto

Filing History

ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION
Feb 5, 2019 MAB4
ABANDONMENT - AFTER INTER PARTES DECISION
Feb 5, 2019 ABN4
OPPOSITION TERMINATED NO. 999999
Feb 5, 2019 OP.T
OPPOSITION DISMISSED NO. 999999
Feb 5, 2019 OP.D
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 2, 2016 TCCA
OPPOSITION INSTITUTED NO. 999999
Sep 22, 2015 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Jun 22, 2015 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 26, 2015 NPUB
PUBLISHED FOR OPPOSITION
May 26, 2015 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 6, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 17, 2015 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 14, 2015 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 19, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 19, 2015 CRFA
ASSIGNED TO LIE
Mar 12, 2015 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 22, 2014 GNRN
NON-FINAL ACTION E-MAILED
Sep 22, 2014 GNRT
NON-FINAL ACTION WRITTEN
Sep 22, 2014 CNRT
ASSIGNED TO EXAMINER
Sep 16, 2014 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 18, 2014 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 17, 2014 NWOS
NEW APPLICATION ENTERED
Jun 7, 2014 NWAP